Vanguard Mid-Cap Growth ETF (VOT) returned 0.59% over the past year. SPDR S&P 500 ETF (SPY) delivered 13.9%. VOT’s five-year return of 26.75% shows the growth filter hasn’t consistently identified ...

Spencer Hackett is a Research Analyst and Portfolio Manager at Grandeur Peak Global Advisors. He is the firm’s Guardian Portfolio Manager of the Global Contrarian Fund (GPGCX), and a Portfolio Manager ...

Learn how to simulate a sliding bead on a tilting wire using Python! Step-by-step tutorial for physics simulations and numerical methods. 🖥️📐 #PythonPhysics #PhysicsSimulation #SlidingBead ...

In this tutorial, we use GlowScript VPython to build a dipole electric field simulation step by step. Learn how to model charges, compute field vectors, and create an interactive visualization that ...

Closed-end funds offer an attractive investment class that covers various asset classes and promises high distributions to income investors. They can also offer reasonable total returns if the ...

Check out our Week 12 update to help you in NBA Fantasy — Salary Cap Edition. Jack Nelson, NBA.com The 76ers’ Tyrese Maxey continues to craft a career-best season with 58.0 fantasy points per game.

Wasatch Global Investors, an asset management company, released its “Wasatch Micro-Cap Fund” third-quarter 2025 investor letter. Microcap stocks reported strong results in the quarter, due to the ...

Humacyte, Inc. (NASDAQ:HUMA) is one of the best micro-cap stocks to invest in. In mid-November, Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte, Inc. (NASDAQ:HUMA) stock and set a ...

Naperville Planning and Zoning commissioners like the idea of a racing simulation center opening on Route 59, and think it could be busy, but it’s contingent on the Naperville City Council approving ...

Aug 29 (Reuters) - Super Micro Computer's (SMCI.O), opens new tab shares fell nearly 5% on Friday after the artificial intelligence-optimized server maker reiterated weaknesses in internal control ...

Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:AIM) is ...